静脉注射铁性碳素马尔托治疗心力衰竭患者的铁缺乏症:一个元分析与试验顺序分析
Laila Shalabi1, Ahmed Ibrahim2, Shrouk Ramadan3
1Faculty of Medicine, Gharyan University, Gharyan, Libya.
European journal of pharmacology
|November 2, 2025
概括
静脉注射铁性碳酸 (FCM) 显著降低了铁缺乏症患者的心力衰竭住院和心血管死亡的数量. 这种治疗支持其作为改善心力衰竭结果的向治疗的使用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 缺铁影响33-50%的慢性心力衰竭患者,与预后较差相关.
- 静脉注射 (IV) 铁性碳酸 (FCM) 是这种人群的潜在治疗剂.
- 评估FCM对心力衰竭结果的影响对于临床实践至关重要.
研究的目的:
- 为了评估慢性心力衰竭和铁缺乏症患者IV铁性碳糖糖糖 (FCM) 的疗效.
- 确定FCM对关键心力衰竭相关终点的影响,包括住院和死亡率.
主要方法:
- 在主要数据库 (PubMed,Scopus,Cochrane图书馆,Web of Science) 进行了对随机对照试验 (RCT) 的系统文献审查,截至2025年5月.
- 聚合风险比率 (RRs) 用固定效应模型计算了主要结果 (心力衰竭住院治疗或心血管死亡),心力衰竭住院治疗总数和所有原因住院治疗总数.
- 使用试验顺序分析 (TSA) 来验证研究结果的稳定性和统计能力.
主要成果:
- 涉及7491名患者的9个RCT表明,FCM显著降低了心力衰竭住院或心血管死亡的风险 (RR 0.89,P = 0.0016).
- FCM还显著降低了心力衰竭住院 (RR 0.82,P<0.0001) 和心血管死亡 (RR 0.89,P=0.0384).
- 在所有原因的住院总数中没有发现显著差异 (RR 0.93,P = 0.0830),尽管TSA证实了主要结果的确证据.
结论:
- 铁性碳酸 (FCM) 有效地减少心力衰竭住院和心血管死亡在患有缺铁心力衰竭的患者.
- 虽然FCM没有显著影响全因住院率,但它对特定心血管结果的好处支持其作为有针对性的治疗策略的作用.
- 这些发现强调了解决缺铁问题在心力衰竭管理中的重要性.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
245
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
245
01:30Heart Failure V: Medical Management
208
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
208
01:30Heart Failure IV: Classification and Diagnostic Evaluation
310
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
310
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:30Heart Failure VII: Nursing Interventions
408
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
408
01:26Heart Failure III: Clinical Manifestations
462
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
462